Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in Fuchs' Corneal Endothelial Dystrophy
NCT02653391Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elamipretide in Fuchs Corneal Endothelial Dystrophy (FECD), sponsored by Stealth BioTherapeutics. Primary endpoints: Incidence and Severity of Ocular Treatment-Emergent Adverse Events at 16 weeks, Incidence and Severity of Systemic Adverse Events at 16 weeks and 2 more. Started Feb 2016; status: completed.
02
Drugs
elamipretide
03
Conditions
Fuchs Corneal Endothelial Dystrophy (FECD)
Beyond the preview
Go deeper on NCT02653391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653391.